Amrix

Amunix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing next-generation T-cell engagers (TCEs) and cytokine therapies for the treatment of solid tumors. The company's proprietary XTEN platform utilizes a biodegradable polymer to extend the half-life of therapeutic proteins while maintaining low immunogenicity. Its lead technology, Pro-XTEN, creates masked protease-activatable therapies that are designed to remain inactive in systemic circulation and selectively activate within the tumor microenvironment to minimize off-tumor toxicity. Amunix was acquired by Sanofi in early 2022 to bolster its oncology pipeline with high-precision immunotherapy candidates.